15 August 2018
Visiongain’s new report Antithrombotic Drugs Market 2017 – 2027: Anticoagulants, Antiplatelets, Fibrinolytics indicates that the antithrombotic drugs market will see $26.4bn in spending in 2021.
The revenue of the antithrombotic drugs market in 2016 is estimated at $18.08bn and is expected to grow at a CAGR of 7.9% in the first half of the forecast period. The anticoagulants segment accounted for the largest share of the market in 2016, this segment held 58.5% of the antithrombotic drugs market.
The lead analyst of this report said: “The risk of thrombosis increases with age, thus the prevalence of this group of diseases is increasing with the aging population of the developed world. Additionally, obesity and immobility are also significant risk factors for thrombotic disease.
This increasing demand for antithrombotic drug treatment combined with the high profile severity of thrombotic disease means there is a constant demand for drugs with improved safety, efficacy and administration. R&D activity has resulted in the launch of several novel drugs in recent years such as the direct thrombin inhibitor Pradaxa and the factor Xa inhibitors Xarelto and Eliquis, and more recently, Zontivity and Lixiana/Savaysa. In a market where generic drugs are major competitors in terms of volume of sales, these novel drugs are significant growth drivers.”
The 186-page report contains 84 tables and 69 figures that add visual analysis in order to explain the developing trends within the Antithrombotic Drugs Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the antithrombotic drugs market and its leading submarkets: Anticoagulants, Antiplatelets, Fibrinolytics.
The 186-page report offers market forecasts for the leading drugs in this market, including: Direct factor Xa inhibitors, Heparins, Direct thrombin inhibitors, Vitamin K antagonists, Xarelto, Plavix, Lovenox, Eliquis, Pradaxa, Activase, Brilinta/Brilique, Aspirin Cardio, Effient, Aggrenox/Asasantin, Fragmin, Pletal, Angiomax/Angiox.
This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
Our work discusses the leading companies in the antithrombotic drugs market. Our study also discusses the SWOT and STEP analysis of the antithrombotic drugs market. Moreover, our report provides revenue forecast for the leading regional and national market: the US, Japan, EU5 (the UK, Germany, France, Spain, and Italy), BRIC (Brazil, Russia, India, and China) and RoW.
The report Antithrombotic Drugs Market 2017 – 2027: Anticoagulants, Antiplatelets, Fibrinolytics report will be of value to anyone who wants to better understand the antithrombotic drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the antithrombotic drugs market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.